New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 20, 2014
10:00 EDTARUN, UBNT, ZIOP, ZLTQ, CNQ, CVE, PXD, KLAC, LRCX, RKUS, DATA, REPH, CAMP, CRL, SCOR, CVD, DWCH, GIMO, MSTR, QLIK, AMATOn The Fly: Analyst Initiation Summary
Aruba Networks (ARUN) initiated with a Neutral at Macquarie... CalAmp (CAMP) initiated with a Neutral at Macquarie... Charles River Labs (CRL) initiated with a Hold at KeyBanc... comScore (SCOR) initiated with a Buy at Brean Capital... Covance (CVD) initiated with a Buy at KeyBanc... Datawatch (DWCH) initiated with a Buy at B. Riley... Flexion (FLXN) initiated with a Buy at Janney Capital... Gigamon (GIMO) initiated with a Buy at Needham... MicroStrategy (MSTR) initiated with a Neutral at B. Riley... Qlik Technologies (QLIK) initiated with a Neutral at B. Riley... Quintiles (Q) initiated with a Hold at KeyBanc... Recro Pharma (REPH) initiated with a Buy at Brean Capital... Ruckus Wireless (RKUS) initiated with an Outperform at Macquarie... Tableau (DATA) initiated with a Buy at B. Riley... Ubiquiti Networks (UBNT) initiated with an Outperform at Macquarie... ZELTIQ (ZLTQ) initiated with a Buy at Stifel... Ziopharm (ZIOP) initiated with a Buy at Mizuho... Pioneer Natural (PXD) initiated with a Market Perform at BMO Capital... Canadian Natural (CNQ) initiated with an Overweight at Morgan Stanley... Cenovus Energy (CVE) initiated with an Equal Weight at Morgan Stanley... KLA-Tencor (KLAC) initiated with a Neutral at Nomura... Lam Research (LRCX) initiated with a Buy at Nomura... Applied Materials (AMAT) initiated with a Buy at Nomura.
News For ARUN;CAMP;CRL;SCOR;CVD;DWCH;GIMO;MSTR;QLIK;REPH;DATA;RKUS;UBNT;ZIOP;ZLTQ;CNQ;CVE;PXD;KLAC;LRCX;AMAT From The Last 14 Days
Check below for free stories on ARUN;CAMP;CRL;SCOR;CVD;DWCH;GIMO;MSTR;QLIK;REPH;DATA;RKUS;UBNT;ZIOP;ZLTQ;CNQ;CVE;PXD;KLAC;LRCX;AMAT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
July 24, 2014
16:38 EDTKLACKLA-Tencor reports Q4 EPS 80c, consensus 86c
Subscribe for More Information
16:22 EDTQLIKQlik Technologies sees FY14 EPS 23c-27c, consensus 25c
Subscribe for More Information
16:21 EDTQLIKQlik Technologies sees Q3 EPS (2c)-1c
Subscribe for More Information
16:20 EDTQLIKQlik Technologies reports Q2 EPS 2c, consensus (3c)
Subscribe for More Information
10:00 EDTRKUSRuckus Wireless upgraded to Conviction Buy from Buy at Goldman (pre-open)
Pre-open, Goldman added Ruckus Wireless to the Conviction Buy List citing relative valuation, strong secular headwinds, share gains, and new product introductions. Price target is remains $18.
09:12 EDTREPHOpaleye Management reports 5.12% passive stake in Recro Pharma
Subscribe for More Information
06:02 EDTAMATApplied Materials implied volatility of 38 at upper end of index mean range
July 23, 2014
16:09 EDTDWCHDatawatch reports Q3 adjusted EPS (24c), consensus (24c)
Subscribe for More Information
05:53 EDTAMATStocks with implied volatility movement; IP AMAT
Subscribe for More Information
July 22, 2014
16:12 EDTGIMOGigamon appoints Mike Burns as CFO
Subscribe for More Information
12:53 EDTAMATApplied Materials drops following report of opposition to merger
Subscribe for More Information
12:19 EDTAMATApplied Materials merger report 'pure speculation,' says Stifel
Subscribe for More Information
10:29 EDTAMATApplied Materials weakness a buying opportunity, says ISI Group
Subscribe for More Information
09:47 EDTAMATApplied Materials sees strong opposition to merger in China, DealReporter says
The proposed merger of Applied Materials (AMAT) with Tokyo Electron is facing strong opposition from Chinese regulators, said DealReporter, according to contacts.
07:15 EDTZIOPZiopharm announces expansion of oncology programs with Intrexon
Ziopharm (ZIOP) announced the expansion of synthetic immuno-oncology programs in conjunction with Intrexon (XON) to include chimeric antigen receptor T-cell, or CAR-T, therapy. Additionally the company has provided an update on its development efforts with the proprietary RheoSwitch Therapeutic System, or RTS, platform, an inducible regulator for expression of therapeutic molecules through administration of an oral activator ligand, as well as its clinical program with Ad-RTS-IL-12, a novel DNA-based therapeutic candidate for the controlled expression of IL-12. CAR-T cells represent an emerging, high value immunological therapy that can target and destroy cancer cells displaying "personalized" fingerprints, yet current approaches feature challenges associated with toxicity, off-target effects, and uneconomical manufacturing. Intrexon possesses the integrated technology platforms, molecular engineering, systems biology, and cell engineering capabilities required to overcome these challenges and fully realize the potential of CAR]T cell therapies. Most significantly, utilization of the RTS platform will facilitate exquisite regulation of one or more bioeffectors in CAR-T cells enabling physicians to control systemic effects of cell therapies with an appropriate dosing regimen of the oral activator ligand, and eventually bring about improved safety and efficacy of these and related therapeutic strategies. Further preclinical work is underway in this promising area of study, and ZIOPHARM and Intrexon expect to provide a progress update in the second half of 2014.
July 21, 2014
13:15 EDTSCORGoogle ranked as top online video content property in June
Subscribe for More Information
10:02 EDTQLIKOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:11 EDTQLIKQlik Technologies risk/reward favorable, says Morgan Stanley
Morgan Stanley said Qlik expectations are low and risk/reward is favorable. The firm believes the QlikView Next release will lead to improved product positioning and sales execution and creates opportunities with business users.
08:11 EDTDATATableau risk/reward favorable, says Morgan Stanley
Subscribe for More Information
05:28 EDTQLIKQlik Technologies upgraded to Overweight from Equal Weight at Barclays
Barclays upgraded Qlik Technologies to Overweight citing an attractive valuation and the upcoming release of QV.Next, which the firm believes could drive meaningful upside. It keeps a $31 price target for shares.
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use